Creating smarter ways to fight bacteria

Leading the advancement of technologies and products that break up biofilms and destroy bacteria.
For over 20 years Kane Biotech’s R+D division has been developing new technologies and innovations leading to 67 patents and patents pending in biotechnology focusing primarily on biofilm.
About Us Research & Development
67
67

Patents and Patents Pending

Kane Wound Care & Surgical

Biofilms are pervasive and represent the most prevalent bacterial mode of growth. The current wound care global market is expected to reach US $22 billion by 2022.

Learn More

Kane Dermatology

The strategic focus of the Kane Dermatology subsidiary is to develop and sell non-prescription consumables to end customers that address minor health ailments where biofilms contribute to the problem.

Learn More

Understanding Biofilms

The study of biofilms has increased significantly in recent years due to the growing awareness of the pervasiveness and impact of biofilms on human and animal health, as well as natural and industrial systems.

Learn About Biofilms
Kane Wound & Surgical Care Feature

revyve™ Antimicrobial Wound Gel

Why would you use any other wound gel?

  • The revyve™ Antimicrobial Wound Gel is a combination of Kane’s patented coactiv+™ technology in a thermo-reversible gel that provides a moist environment best suited for wound healing.
  • revyve™ Antimicrobial Wound Gel undergoes a reversible transformation from liquid to gel with temperature. This allows the wound gel to be easily applied, stay on the wound, and easy to rinse off, making it ideal for sensitive wounds.
  • Accessible for patients. The revyve™ Antimicrobial Wound Gel fits within reimbursement of US $21.61/oz with US $64.83/3oz for the monthly allowable - one of the ONLY wound gels within reimbursement.
Learn More

Renderings shown are for illustrations purpose only.
These drawings are not meant to be an exact rendition.

Kane Dermatology Feature

DermaKB™

A new scalp detoxifier and shampoo designed to break down biofilm.

Recent research has indicated that the persistence of biofilms may be linked with aggravating the symptoms associated with common scalp conditions, such as dandruff and seborrheic dermatitis.

Kane Dermatology launched a shampoo, shampoo bar and scalp detoxifier under the DermaKB™ brand as the first products in their new skin care line. The products are sold direct-to-consumer through Amazon and Kane’s online commerce site.

Kane had conducted an extensive consumer trial on DermaKB™ scalp care products with coactiv+™ across North America with 4,500 participants suffering from a variety of common scalp conditions. Over 1,400 extensive questionnaires were completed, and of the participants who used both the DermaKB™ Detoxifier and Shampoo and rated their symptom as either extreme or severe before the trial, 82% identified an improvement in their symptom after using the products.

From Our Video Library

View our collection of videos on everything from business updates to industry webinars.

02 revyve™ Antimicrobial Wound Gel Update | Kane Biotech Product Development Video Series

2024 Product Development Video Series

As part of our commitment to communicate more frequently with our investors in 2024, Kane Biotech Inc. introduces a new video series, with each video focused on one key initiative that is driving our business forward.

Watch The Video Series

Kane Biotech Video Archive

From business update series to industry webinars, Kane Biotech has a number of past videos to watch at your leisure.

Watch Past Videos

The Latest Articles from Our Kane Blog

Click the images or titles below to read the full articles.

  • Raising Kane: The Secret to How Kane Biotech Got Its Name
    by Kane Biotech on June 22, 2023 at 5:38 pm

    What is in a company name? The name Kane Biotech is a tribute to the fond memories of the company’s founder who lived for many years in a small, rural town in Manitoba, called Kane. In 1906, John H. Kane, a grain buyer from the

  • Kane Biotech Announces 2023 Achievements
    by Kane Biotech on June 9, 2023 at 4:33 pm

    Kane aims to disrupt global wound care hydrogel market with its first FDA cleared medical device and announces new partnerships and licensing agreements  Kane Biotech has announced several partnerships and licensing agreements in both wound care and animal health in 2023. The recent announcement of

  • Kane Biotech in the News 2023
    by Kane Biotech on January 31, 2023 at 3:35 pm

    In 2023, Kane Biotech has been featured in several news media articles, including  BNN Bloomberg and Benzinga, as well as a podcast with proactiveinvestors.com. Kane is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. With a

  • DermaKB™ Offers Personalized Scalp Solutions Developed by Kane Biotech
    by Kane Biotech on January 16, 2023 at 3:59 pm

    The largest organ in a human body is the skin, and each person’s skin is 100% unique. That is why it is so important that your scalp products are perfectly tailored to your unique skin challenges. DermaKB™ products are developed by Kane Biotech, who is leading the

  • The History of Wounds: From Early Humans to Modern Technologies
    by Kane Biotech on January 3, 2023 at 4:34 pm

    It is fascinating to think of how the earliest humans learned how to treat wounds, as the earliest historical evidence dates back as far back as 2200 BC with a clay tablet that bears three images of a wound being washed, a plaster of mud

View All Articles

Investor Relations

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (67 patents and patents pending, trade secrets and trademarks) and products developed by the Company's own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex™, bluestem™, bluestem®, silkstem™, goldstem™, coactiv+™, coactiv+®, DermaKB™ and DermaKB Biofilm™ are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.

View Kane Biotech’s latest financial reports, press releases, and presentations to provide you with insight into our business and investor relations.

Corporate News Investor Section

Our Location

Kane Biotech’s offices and laboratories are located in the University of Manitoba Smartpark Innovation Hub. It includes two independent analytical laboratories and three independent and well-equipped microbiology suites.

Click on the Matterport links to take an immersive 3D virtual tour of Kane Biotech’s offices and laboratories.

Matterport 360° Office Tour Matterport 360° Lab Tour